References

Unresolved reference

External reference

Zoonotic potential of influenza a viruses: a comprehensive overview

10.3390/v10090497 · 2018 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

On the brink: H5N1 and the risk to human health

2025 · External reference

Unresolved reference

External reference

Enhancing the response to avian influenza in the US and globally

2025 · External reference

An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection

10.1038/s41541-024-00988-9 · 2024 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications

10.1186/s12985-025-02645-6 · 2025 · External reference

A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults

10.1016/j.vaccine.2025.126847 · 2025 · External reference

Efficacy, immunogenicity, and safety of modified mRNA influenza vaccine

10.1056/nejmoa2416779 · 2025 · External reference

229. mRNA-1010, an mRNA-based influenza vaccine, is safe and efficacious in adults aged ≥50 years

10.1093/ofid/ofaf695.012 · 2026 · External reference

Influenza A viruses: new research developments

10.1038/nrmicro2613 · 2011 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine

10.1371/journal.pone.0049704 · 2012 · External reference

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine

10.1056/nejmoa055778 · 2006 · External reference

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant

10.1093/infdis/jiq093 · 2011 · External reference

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial

10.1001/jama.2014.12854 · 2014 · External reference

Safety and immunogenicity of influenza A/H5N8 virus vaccine in healthy adults: durability and cross-reactivity of antibody responses

10.1093/cid/ciac982 · 2023 · External reference

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults

10.1126/scitranslmed.3008761 · 2014 · External reference

A phase 2 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of different prime-boost vaccination schedules of 2013 and 2017 A(H7N9) inactivated influenza virus vaccines administered with and without AS03 adjuvant in healthy US adults

10.1093/cid/ciae173 · 2024 · External reference

Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older

10.1016/j.vaccine.2020.11.051 · 2021 · External reference

Unresolved reference

External reference

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study

10.1093/infdis/jir172 · 2011 · External reference

Analyses of safety profile and homologous antibody responses to a mammalian cell-based, MF59-adjuvanted, A/H5N1, pandemic influenza vaccine across four phase II/III clinical trials in healthy children, adults, and older adults

10.3390/vaccines9121468 · 2021 · External reference

Highly pathogenic avian influenza A(H5N1) virus infection in a dairy farm worker

10.1056/nejmc2405371 · 2024 · External reference